Skip to content
DataLookout
Menu

NCT07933835

A Study to Learn How Different Amounts of the Study Medicine Called PF-08166744 Are Tolerated and Act in Healthy Adults.

StatusNot Yet Recruiting
PhasePhase 1
SponsorPfizer
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Timeframe: Part A: Day 1 through Day 113; Part B: Day 1 through Day 127
Number of Participants With Clinical Laboratory Abnormalities
Timeframe: Part A: Day 1 through Day 113; Part B: Day 1 through Day 127
Number of Participants With Vital Sign Abnormalities
Timeframe: Part A: Day 1 through Day 113; Part B: Day 1 through Day 127
Number of Participants With Electrocardiogram (ECG) Abnormalities
Timeframe: Part A: Day 1 through Day 113; Part B: Day 1 through Day 127

Secondary (9)

SAD (Part A): Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of PF-08166744
SAD (Part A): Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of PF-08166744
SAD (Part A): Maximum Observed Plasma Concentration (Cmax) of PF-08166744
SAD (Part A): Time to Maximum Observed Plasma Concentration (Tmax) of PF-08166744
SAD (Part A): Terminal Elimination Half-Life (t1/2) of PF-08166744
Show 4 moreShow less
MAD (Part B): Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUCtau) of PF-08166744
MAD (Part B): Maximum Observed Plasma Concentration (Cmax) of PF-08166744
MAD (Part B): Time to Maximum Observed Plasma Concentration (Tmax) of PF-08166744
MAD (Part B): Terminal Elimination Half-Life (t1/2) of PF-08166744

Arms and interventions

Arm 1: PF-08166744Experimental

Participants in Part A will receive a single ascending dose of PF-08166744 by subcutaneous or intravenous administration according to the assigned cohort. Participants in Part B will receive multiple ascending subcutaneous doses of PF-08166744 according to the assigned cohort.

Arm 2: PlaceboPlacebo comparator

Participants in Part A will receive a single dose of placebo by subcutaneous or intravenous administration according to the assigned cohort. Participants in Part B will receive multiple subcutaneous doses of placebo according to the assigned cohort.

Drugs: PF-08166744, Placebo